- During the phase I portion, which is now closed, for chronic GVHD prophylaxis, four doses of MLN9708 were administered orally (to patients undergoing either matched sibling or unrelated donor transplantation) on days 1, 8, 15 and 22, starting on day +60 to +74 post allogeneic HCT.